Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse
BMC Cancer, 10/20/09

Lallemant B et al. – IL1RN, MAL and MMP1 are prospective tumor diagnostic markers for HNSCC. MMP1 overexpression is the most promising marker, and its detection could help identify tumor cells in tissue or saliva.

Methods

For period of 2 years, we systematically collected tumor tissue, normal matched mucosa and saliva of patients diagnosed with primary untreated HNSCC
Expression levels of the nine genes of interest were measured by RT-qPCR in tumor and healthy matched mucosa from 46 patients
MMP1 expression level measured by RT-qPCR in salivary rinse of 51 HNSCC patients and 18 control cases

Results

Dysregulation of 9 genes confirmed by Wilcoxon test
IL1RN, MAL and MMP1 were most efficient diagnostic markers of HNSCC, with ROC AUC >0.95 and both sensitivity and specificity above 91%
No clinically relevant correlation found between gene expression level in tumor and T stage, N stage, tumor grade, global survival or disease-free survival
Preliminary results suggests that with 100% specificity, MMP1 detection in saliva rinse potentially useful for non invasive diagnosis of HNSCC of oral cavity or oropharynx, but technical improvement is needed

<< Previous
Explorative study on the predictive value of systematic...

Next >>
An open-label expanded access study of lapatinib and capecitabine...